Pharma Strategy Blog

Commentary on Pharma & Biotech Oncology / Hematology New Product Development

Posts tagged ‘vlog’

Custirsen – a new treatment for castrate resistant prostate cancer?

By on August 8, 2011

I’ve been following the development of Oncogenex’s custirsen for a while based on various posters presented at meetings such as ASCO and AUA, but with the publication of phase II data in prostate cancer, it seems a good time to discuss the compound in more detail.

According to Oncogenex:

“OGX-011, also known as custirsen sodium, inhibits the production of clusterin, a protein that is associated with treatment resistance in a number of solid tumors, including prostate, breast, non-small cell lung, ovarian, and bladder cancers.”

This is a preview of Custirsen – a new treatment for castrate resistant prostate cancer?. Read the full post

2 Comments

A vlog update on advanced prostate cancer from the AUA 2011 meeting

By on May 16, 2011

After attending numerous basic research and clinical updates at the American Urologic Association (AUA) annual meeting in Washington DC, it is clear that the new and emerging therapies are not going to stop at the three grand crus from 2010.

Recently, abiraterone acetate (Zytiga) was approved, but there are a number of critical issues that need to considered, including:

  1. Sequencing
  2. Combinations
  3. Cost
  4. Patient selection

As we learn more about the molecular mechanisms behind resistance to androgen receptor signaling (up and downstream) and new targets emerge, so it may be possible to improve patient outcomes in castration-resitant prostate cancer.

This is a preview of A vlog update on advanced prostate cancer from the AUA 2011 meeting. Read the full post

3 Comments